Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Intercept Pharmaceuticals (NASDAQ:ICPT), a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic liver disease, vaulted higher by as much as 75% following four price target upgrades from Wall Street firms.
So what: Following yesterday's 281% romp higher (a gain of better than $200 per share) on the heels of news that its mid-stage study of obeticholic acid (OCA) for nonalcoholic steathohepatitis (NASH) was ended early because of statistically significant efficacy, four research firms drastically boosted their price targets on Intercept. Oppenheimer upped its target price from $94 to $360; BMO Capital jumped its target price to $375 from $270; Citigroup moved its target from $60 to $400; and the whopper of them all was Bank of America Merrill Lynch, which boosted its price target from $81 to $872! Bank of America Merrill Lynch is predicting peak OCA sales of $4 billion.
Now what: With a two-day move of nearly $400 per share and more than 500%, the magnitude of this move is starting to border on silly -- primarily because today's move appears to be nothing more than a rally based on analyst comments, which are often fleeting and rarely have any bearing on our long-term investing thesis. I'll repeat what I said yesterday, which is that an enormous move like this had best be met with perfect clinical data and (if approved) launch execution from here on out, or this premium could disappear just as fast. Following Intercept's historic run, I see no better recourse than to stick to the sidelines, far away from this highly volatile issue until we've had some time for the dust to clear.
This top stock may even have more potential than Intercept
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Fool contributor Sean Williams owns shares of Bank of America, but has no material interest in any other companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool owns shares of , and recommends Bank of America. It also owns shares of Citigroup. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.